Dolutegravir/rilpivirine, sold under the brand name Juluca, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[7] It contains the medicines dolutegravir and rilpivirine. It is taken orally (by mouth).
The most common adverse reactions (of all severity grades) are diarrhea and headache.
Dolutegravir/rilpivirine was approved for use in the United States in November 2017,[8][9][10] and for use in the European Union in May 2018.[11]